Your Gut Bacteria Could Reveal Which Infection You’ll Get After Brain Surgery

If you or someone you love is heading into brain surgery, infection risk is one of the quiet worries hanging over the recovery. A new study of 90 neurocritical care patients suggests part of the answer may already be sitting in the gut before an infection ever shows up: the mix of bacteria and their metabolic byproducts in stool, sampled within the first 24 hours after surgery, looked strikingly different depending on which kind of infection a patient went on to develop. It is early, cross-sectional evidence, not a bedside test, but it points to a biological fingerprint that could eventually help doctors act sooner.

Key Takeaways

• In 90 neurocritical care patients, gut bacteria and short-chain fatty acid (SCFA) patterns measured within 24 hours of surgery differed by which infection a patient later developed: pulmonary infection (PI), intracranial infection (IC), or none.
• A six-genus bacterial panel (Enterococcus, Faecalibacterium, Dialister, Escherichia-Shigella, Agathobacter, and Blautia) distinguished the three groups with an area under the curve (AUC) of 0.901.
• Pulmonary infection came with more propionate and less butyrate plus a Proteobacteria expansion; intracranial infection came with more butyrate, less propionate, and more branched-chain SCFAs plus Enterococcus and Staphylococcus enrichment.
• This is a single-center, cross-sectional study of 90 people; it shows association, not proof the microbiome causes infection, and the panel has not been tested in a separate group of patients.

Gut Bacteria and SCFA Signatures Split by Infection Type

A study of 90 neurocritical care patients recovering from neurosurgery, published in Frontiers in Microbiology, found that gut bacteria and the short-chain fatty acids (SCFAs, acids gut bacteria produce by fermenting fiber) they generate differed depending on which infection a patient developed after surgery. Patients who developed a pulmonary infection (PI, an infection in the lungs) showed higher propionate and lower butyrate along with an expansion of Proteobacteria, a bacterial group that includes many opportunistic pathogens, and specifically more Klebsiella and Escherichia-Shigella. Patients who instead developed an intracranial infection (IC, an infection inside the skull, such as meningitis or a brain abscess) showed the opposite metabolic pattern: more butyrate, less propionate, and a higher share of branched-chain SCFAs, alongside enrichment of Enterococcus, Staphylococcus, and Clostridium. A panel of six bacterial genera, Enterococcus, Faecalibacterium, Dialister, Escherichia-Shigella, Agathobacter, and Blautia, distinguished among the three patient groups with an AUC (a measure of how well a test separates categories, where 1.0 is perfect) of 0.901.

Why This Matters for Neurosurgery Patients and Their Families

Postoperative infection is a major complication after neurosurgery: pulmonary infections occur in roughly 40% of neurocritical care patients, while intracranial infections affect a smaller but more dangerous slice, about 0.7% to 8%, according to the study's own background. Both infection types slow recovery and can worsen long-term neurological outcomes, but doctors currently have no reliable way to tell, in the hours after surgery, which type of infection a given patient is at risk for. That distinction matters because a lung infection and a brain infection call for different antibiotics, different monitoring, and different urgency. For patients and families navigating a neurosurgical recovery, or anyone researching gut-brain and gut-lung connections after worrying about post-op complications, this study is an early signal that the gut might hold a usable clue.

Inside the 90-Patient Cross-Sectional Design

Researchers enrolled 90 patients undergoing neurosurgical procedures out of 820 screened, then split them into three equal groups of 30 based on what happened afterward: an intracranial infection (IC) group, a pulmonary infection (PI) group, and a non-infected control (CON) group. Fecal samples were collected from all patients within 24 hours of surgery and analyzed with 16S rRNA gene sequencing (a method that identifies which bacterial genera are present) and gas chromatography-mass spectrometry (a technique that measures the exact concentration of chemicals like SCFAs). The three groups did not differ significantly in age, sex, or body mass index at baseline, which strengthens the case that the microbial differences tracked with infection outcome rather than pre-existing patient differences. This sits within a broader body of work showing that gut microbiota diversity loss is tied to nosocomial infection risk in critically ill patients generally, and echoes a related cohort study that found preoperative gut microbiota depletion predicts postoperative pneumonia in patients with intracranial lesions.

What This Could Mean If You're Facing Surgery

Nothing about this research changes what a patient should do before or after neurosurgery today. No probiotic, prebiotic, or specific diet was tested here, and the study does not establish that changing gut bacteria would change infection risk. What it does suggest is a plausible future direction: doctors might eventually sample stool right after surgery and get an early hint about which infection to watch for and treat preemptively, before symptoms appear. If you or a family member is preparing for a high-risk neurosurgical procedure, it is reasonable to ask the surgical team what infection-prevention protocols are already standard, rather than asking about a microbiome test that does not yet exist in clinical practice.

Why This Result Needs More Validation Before It's a Real Test

This is a cross-sectional study from a single center, and 30 patients per group is large enough to be informative but too small to be conclusive on its own. The AUC of 0.901 was calculated in the same patients used to build the six-genus panel, not in a separate, independent set, so its real-world accuracy is likely lower than what is reported here. The design also cannot prove that the microbial and SCFA differences caused the infections rather than resulted from them, or from some third factor, such as differences in antibiotic exposure, that the study did not fully capture. The researchers themselves frame the biomarker panel as a "potential" tool for risk stratification, not a validated one.

What Comes Next for Gut-Based Infection Screening

The logical next step is a larger, multi-center, prospective study that samples patients at the same 24-hour post-surgery window, then tests whether the six-genus panel actually predicts, rather than merely correlates with, which infection develops, ideally in a separate validation group. The researchers also flagged specific biological threads worth chasing: why intracranial infection came with such a steep drop in microbial diversity, whether the elevated branched-chain SCFAs in that group reflect harmful protein-fermentation byproducts that damage the gut lining, and how SCFAs like butyrate and propionate shape immune signaling well enough to influence infection susceptibility at distant sites like the lungs and the brain. None of that groundwork exists yet, which is why this remains a research finding, not a clinical tool.

Common Questions

What is the gut-lung axis, and does it apply here? It is the idea that gut bacteria and their metabolites can influence immune activity in the lungs. This study's pulmonary-infection group showed a distinct gut bacterial and SCFA pattern consistent with that broader research area, though it did not directly test lung tissue or immune cells.

What are short-chain fatty acids (SCFAs) and why do they matter? SCFAs are acids like butyrate, propionate, and acetate that gut bacteria produce by fermenting dietary fiber. They feed gut cells, help maintain the gut barrier, and influence immune activity throughout the body, so shifts in their levels can signal broader changes in gut health.

Could this become an actual hospital test? Not yet. The panel needs to be tested in an independent group of patients, ideally across multiple hospitals, before anyone could trust it to predict infection risk in a new patient; this study only shows the pattern exists in one cohort of 90 people.

Does this mean probiotics could prevent these infections? The study did not test any intervention, probiotic or otherwise, so it offers no evidence that changing gut bacteria would lower infection risk. That would require a separate clinical trial.

References

1. Weirong Sun, Zhen Zhang, Congkai Wang, et al. (2026). Gut microbiota and SCFA signatures in predicting postoperative infection sites in neurocritical care patients. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1933225
2. Jared Schlechte, Amanda Z. Zucoloto, Ian-ling Yu, et al. (2023). Dysbiosis of a microbiota–immune metasystem in critical illness is associated with nosocomial infections. Nature Medicine. https://doi.org/10.1038/s41591-023-02243-5
3. Juan Chen, Zhiyu Li, Yewen Zhan, Qianqian Tan, Jin Li, Hong Pu (2026). Preoperative gut microbiota depletion and metabolomic signatures predict postoperative pneumonia in patients with intracranial space-occupying lesions: a multi-omics prospective cohort study. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1839465
4. Elizabeth R. Mann, Ying Ka Lam, Holm H. Uhlig (2024). Short-chain fatty acids: linking diet, the microbiome and immunity. Nature Reviews Immunology. https://doi.org/10.1038/s41577-024-01014-8